.png "Xtant Medical Holdings (NYSE: XTNT)")
Maxim Group analyst Anthony Vendetti maintained a Buy rating on Xtant Medical Holdings (NYSE: XTNT) today and set a price target of $10. The company’s shares opened today at $7.05.
Vendetti said:
“1Q18 revenue of $17.9M, down 18.8% y/y, was below our estimate of $19.3M, but the company terminated low margin or unprofitable business. Adjusted EBITDA of $1.14M compared to ($0.11M) in 1Q17, was above our estimate of ($0.30M). GAAP EPS of ($0.70), compared to ($3.87) in 1Q17, was narrower than our estimate of ($0.75). Introducing 2020 estimates with revenue of $82.7M and GAAP EPS of ($0.23)..”
Vendetti has an average return of 5.6% when recommending Xtant Medical Holdings.
According to TipRanks.com, Vendetti is ranked #478 out of 4787 analysts.
Xtant Medical Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $10.
See today’s analyst top recommended stocks >>
Based on Xtant Medical Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $28.42 million. In comparison, last year the company had a GAAP net loss of $5.78 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xtant Medical Holdings, Inc. operates as a holding company, which supplies orthopedic and spine surgery products. The company operates through its subsidiaries, Bacterin International, Inc. and X-spine Systems, Inc. Bacterin International develops, manufactures, and markets biologics products to domestic and international markets.
